SCHEMBL19617147

SCHEMBL19617147

Clc1ccc2c(c1)[C]=CCC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 5/20 0.38
HTR2C P28335 5/20 0.38
HTR2B P41595 4/20 0.38
PNMT P11086 1/20 0.36
KDM1A O60341 3/20 0.36
AHR P35869 2/20 0.35
CMA1 P23946 1/20 0.35
F7 P08709 1/20 0.33
PARP1 P09874 1/20 0.33
F3 P13726 1/20 0.33
PARP10 Q53GL7 1/20 0.33
HTR3E A5X5Y0 1/20 0.33
HTR3B O95264 1/20 0.33
HTR3A P46098 1/20 0.33
HTR3D Q70Z44 1/20 0.33
HTR3C Q8WXA8 1/20 0.33
HTR5A P47898 1/20 0.32
ADRB1 P08588 1/20 0.32
HTR1A P08908 1/20 0.32
ADRA2A P08913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7795183 0.79 AHR (0.37) HTR2AHTR2CHTR2BPNMTKDM1A
SCHEMBL38097 0.70 TSHR (0.36) HTR2C
SCHEMBL3108863 0.68 KDM1A (0.41) HTR2AHTR2CHTR2BPNMTKDM1A
SCHEMBL2504099 0.68 MEN1 (0.36)
SCHEMBL208849 0.64 AHR (0.43) HTR2AHTR2CHTR2BPNMTKDM1A
SCHEMBL2280630 0.64 HTR2A (0.42) HTR2AHTR2CHTR2BPNMTKDM1A
SCHEMBL15962624 0.63
SCHEMBL28354723 0.63 HTR2A (0.50) HTR2AHTR2CHTR2BPNMTKDM1A
Ammonia Solution, Strong SCHEMBL10465265 0.61 HTR2A (0.67) HTR2AHTR2CHTR2BPNMTKDM1A
SCHEMBL6956357 0.61 AHR (0.59) HTR2AHTR2CHTR2BPNMTAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710439-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-09-23 EP disclosed
EP-3458445-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2019-03-27 EP disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 WO disclosed